LOS ANGELES, CA /  CorporatePRwire  / August 29, 2025 / LifeRx.md today announced a definitive expansion of its clinical services. After establishing a permanent leadership position in GLP and GIP metabolic care, LifeRx.md will introduce clinician-supervised NAD+ and methylene blue therapies to its treatment menu, effective September 2025.

This expansion is a permanent enhancement to LifeRx.md’s clinician-led platform. The new therapies will be delivered only after patients complete a medical assessment and receive a personalized treatment plan from a licensed clinician. All treatments will be provided under direct medical supervision, with established follow-up and monitoring protocols in place.

“Maturing our clinical offerings is a strategic step that strengthens LifeRx.md’s commitment to safe, medically supervised care,” said Nic Sementas, Chief Advocacy Officer of LifeRx.md. “These additions expand therapeutic options for patients who seek clinician-guided programs that build on our GLP and GIP work. Our clinical teams will manage eligibility, dosing where applicable, and ongoing follow-up to ensure each patient receives an individualized plan.”

Key facts about the expansion:
• Timing: New services will be available beginning September 2025.
• Treatments added: NAD+ and methylene blue will be offered as clinician-supervised options.
• Clinical process: Every patient will undergo an intake assessment, medical screening, and a clinician review before any treatment.
• Individualized care: Treatment plans will be tailored to the patient’s medical history, medications, and clinical needs.
• Safety and monitoring: Scheduled follow-up, documentation of clinical metrics, and medical oversight will be built into each patient plan.

LifeRx.md will implement the expansion through a phased rollout designed to ensure that clinical protocols, staff training, supply logistics, and patient education materials are complete. The company will make clear, clinician-authored resources available that outline eligibility criteria, any contraindications, the assessment process, and the required follow-up schedule.

LifeRx.md’s platform connects patients with licensed medical professionals for telehealth consultations and medically supervised treatment programs. The company’s model emphasizes clinical assessment, patient safety, and clear medical oversight for all services provided or coordinated by the platform.

About LifeRx.md
LifeRx.md is a clinical and telehealth platform focused on delivering medically supervised metabolic care and related therapies. The company offers structured treatment programs guided by licensed clinicians and designed to meet individual patient needs. LifeRx.md provides telehealth access, clinician assessment, and ongoing medical monitoring for patients seeking evidence-informed metabolic and cellular support options.

The post LifeRx.md Expands Clinical Services to Include NAD+ and Methylene Blue; Confirms Leadership in GLP and GIP Metabolic Care appeared first on CorporatePRwire.

With today’s healthcare environment placing increasing emphasis on compliance and operational readiness, ComplianceConnect offers expert-led support at every phase:

• Preparation – Through mock audits, tracer activities, and detailed policy, documentation and processreviews to proactively identify and close gaps.
• Audit Assistance – On-site or virtual guidance during audits to support documentation, team readiness, and reduce compliance risk.
• Post-Audit Recovery – Corrective action planning and remediation to help organizations return to standard and implement lasting improvements, including assistance in developing written Evidence of Standards Compliance and 2567 Plans of Correction.

The division will be led by Lloyd Duplechan, a nationally and internationally recognized expert in healthcare operations, accreditation readiness, and regulatory compliance. A retired Kaiser Permanente Chief Operating Officer, Lloyd brings over 40 years of leadership experience helping healthcare organizations manage high-stakes audits and complex regulatory challenges.

He is a published author and respected speaker. His recent contributions include a peer-reviewed article in the American Medical Association Journal of Ethics^® entitled: How High Reliability Can Facilitate Clinical, Organizational, and Public Health Responses to Global Ecological Health Risks – Archived in the National Institutes of Health (NIH) National Library of Medicine (PubMed) and Europe PMC web; and Developing an EVS Compliance Plan- Using accreditation requirements as a template for a program – published in the American Society for Healthcare Engineering’s Health Facilities Magazine.

Lloyd is widely known for translating complex standards and regulations into practical, result driven strategies. His expertise spans CMS Conditions of Participation / Conditions of Coverage, The Joint Commission CAMH, DNV standards, NFPA Life Safety Code^®, Health Care Facilities Code, and a broad array of regulatory and statutory frameworks.

“This new division reflects enBio’s continued commitment to strategic growth by delivering gold-standard services that help healthcare organizations meet their compliance goals without compromising on quality or value,” said Arthur Zenian, Founder and CEO of enBio Corp. “Lloyd’s experience, including his years of leadership at Kaiser Permanente, positions us to make a meaningful impact for clients navigating ever-evolving regulatory demands.”

“enBio’s approach to operational excellence and client partnership aligns perfectly with my lifelong mission to elevate the quality of healthcare environments, and inspire High Reliability,” said Lloyd Duplechan. “Preparing for an audit is not just about passing a survey-it’s about embedding quality into the culture. I’m honored to lead ComplianceConnect and help providers strengthen compliance while improving care.”

ComplianceConnect joins enBio Corp’s growing portfolio of specialized healthcare service divisions, including:

• Biomedical Services for Hospitals
• Biomedical Services for Clinics
• Hospital Bed Repair & Maintenance
• enBio TalentConnect (healthcare staffing)

To learn more about ComplianceConnect, visit www.enbiocorp.com.

About enBio Corp
enBio Corp is a boutique healthcare services company committed to delivering operational excellence and exceptional value. With tailored support in biomedical repair, staffing, and compliance, enBio partners with healthcare providers nationwide to optimize performance and elevate patient care.

For more information visit: enBio Corp | (818) 953-9976

Source: enBio Corp

The post enBio Corp Launches ComplianceConnect to Support Healthcare Providers with Accreditation and Regulatory Readiness appeared first on CorporatePRwire.

LOS ANGELES, CA / CorporatePRwire / July 21, 2025 / The Light System, a wellness technology company, has officially launched its signature energy-based wellness platform-reviving a powerful but largely under-recognized technology that was developed over 30 years ago. Long studied in the background of bioenergetic science, this immersive system is now gaining attention for its potential to support relaxation, alignment, and energetic balance in a modern wellness setting.

Engineered around light, color, and positive affirmations, The Light System creates an immersive environment using photonic light emissions, sacred geometry, flowing visuals, and harmonic affirmations. The result is a visually and energetically rich space that may help put the body in a better position to heal itself-not by providing a cure, but by supporting the body’s natural energetic alignment.

“We’re not claiming to heal anyone, your body heals itself.” said Jarrod, Chief Operating Officer of The Light System. “What The Light System may do is create an environment where the body can shift out of stress, settle into balance, and begin to do what it’s designed to do-restore itself.”

How It Works
The Light System operates through a process the company refers to as “photonic collision,” where light and frequency waves emitted from two synchronized screens converge at the center of the unit. Combined with carefully programmed sacred geometry, flowing motion, color therapy, and positive affirmations, this field may influence the body’s biofield in subtle but meaningful ways.

The system includes 16 pre-set energetic programs, such as “Rejuvenation,” “Clarity,” and “Alignment,” designed to guide the user’s internal experience through immersive visuals and frequency shifts. Users simply sit or recline within the environment while the system surrounds them in a multi-sensory experience that many say leaves them feeling recharged and emotionally balanced.

User Experiences
The Light System is not a medical device and does not diagnose, treat, or cure any conditions. However, users have reported that their sessions may help with stress reduction, mental clarity, improved sleep, and a greater sense of calm. These effects are individual and anecdotal, not guaranteed.

“People tell us they feel like their nervous system finally has a chance to reset,” Jarrod added. “It’s less about targeting symptoms and more about supporting the body’s own intelligence.”

Product Line & Availability
The Light System is available in a range of sizes to accommodate personal and professional spaces. Smaller setups like the Cube and Pyramid models are designed for home or compact use, while larger-scale systems such as The Dream and The Awakening are used in wellness centers and immersive studios.

Learn More about The Light System at www.thelightsystems.com.

Follow The Light System on Instagram at: @thelight.system

About The Light System
The Light System is a U.S.-based energy wellness technology company offering frequency-based environments designed to support the body’s natural energetic flow. Drawing on 30 years of research, The Light System blends light, sound, scalar energy, color, and sacred geometry into a non-invasive, immersive experience. While not a medical treatment, it may complement wellness routines focused on energy alignment, relaxation, and emotional clarity.

The post The Revolution of Healing is here – The Light System appeared first on CorporatePRwire.

Dr. Abbasi will begin his trip in Mumbai, where he has been invited to present at SMISS India (Society for Minimally Invasive Spine Surgery). During the conference, Dr. Abbasi will lead a cadaver lab, offering hands-on training to spine surgeons from across the region. His lab will focus on the innovative OLLIF technique—a revolutionary, muscle-sparing approach that reduces operative time, lowers complication rates, and accelerates patient recovery.

Following SMISS, Dr. Abbasi will travel to Bareilly, where Professor Varun Agarwal has invited him to collaborate on advancing spinal education and surgical training in India. In recognition of his contributions to the field, Dr. Abbasi will be appointed as a Professor at Prof. Agarwal’s university, where he will also perform live surgeries, demonstrating the OLLIF technique to local surgeons and medical students.

This partnership reflects Dr. Abbasi’s ongoing commitment to training the next generation of spine surgeons and sharing cutting-edge, patient-centric surgical innovations globally.

“India has some of the most brilliant medical minds and some of the greatest needs when it comes to spine care. I am honored to return and continue working with outstanding colleagues like Prof. Agarwal,” said Dr. Abbasi.

Inspired Spine and Dr. Abbasi remain at the forefront of transforming spinal surgery through education, international collaboration, and a focus on less invasive, more effective treatments.

Contact:
Inspired Spine
(952) 225-5266

The post Dr. Hamid Abbasi Heads to India for Third Educational Tour to Teach OLLIF Procedure appeared first on CorporatePRwire.

IRVINE, CA / CorporatePRwire / July 8, 2025 / Southern California private equity firm IRA Capital (“IRA”) is pleased to announce the acquisition of Reunion Inverness Hospital, a newly developed 49,106 square-foot inpatient rehabilitation facility (“IRF”) located in Englewood, Colorado (the “Property”). Delivered in 2022 and 100% leased through 2047, the facility is operated by a wholly owned subsidiary of Reunion Rehabilitation Hospitals (“Reunion”), one of the nation’s fastest-growing IRF platforms.

Reunion Inverness Hospital is a 40-bed IRF offering high-acuity, post-acute rehabilitative care. The facility features all-private patient rooms, advanced therapy gyms, and outdoor courtyards. It is staffed by specialized rehabilitation physicians, nurses, and therapists providing individualized treatment programs for patients recovering from stroke, brain and spinal cord injuries, orthopedic trauma, and other life-changing conditions. The tenant, Reunion, currently operates seven IRFs across Arizona, Colorado, Florida, and Texas. All Reunion facilities are developed and managed in partnership with Nobis Rehabilitation Partners, a recognized leader in IRF operations with 22 facilities under management across 12 states.

The acquisition aligns with IRA Capital’s strategy of investing in best-in-class, mission-critical healthcare assets that deliver high-acuity care in growing markets. According to IRA Capital co-founder Amer Kasm, “Reunion Inverness Hospital represents a strategic addition to our portfolio. With a 22-year remaining lease term, Class-A buildout, and strong operator performance, the facility underscores our focus on long-term income durability and the continued shift toward specialized, outcome-driven care in lower-cost settings.”

About IRA Capital

Founded in 2010, IRA Capital is a Southern California-based private equity firm specializing in real estate investments. IRA primarily invests in commercial real estate assets throughout the United States, with an overweight concentration within the medical and healthcare sectors. To date, the firm has acquired over 11.5 million square feet of property across 28 states, with a total capitalization exceeding $3.9 billion. IRA partners with pension funds, institutions, and family offices to invest in high-quality assets. To learn more, visit www.iracapital.com.

For more information, please contact:
IRA Capital Investor Relations
investorrelations@iracapital.com

The post IRA Capital Acquires Premier Inpatient Rehabilitation Facility in Denver appeared first on CorporatePRwire.

NEW YORK CITY, NY / CorporatePRwire / June 25, 2025 / Silo Pharma, Inc. (Nasdaq:SILO)(“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, today announced that it has entered into a non-binding letter of intent to form a strategic 50:50 joint venture with Hoth Therapeutics, Inc. (Nasdaq: HOTH) to develop and commercialize a potential treatment for obesity and metabolic disease based on technology Hoth has exclusively licensed from the U.S. Department of Veterans Affairs (VA) that was co-developed by the VA and Emory University.

The novel therapeutic platform centers on glial cell line-derived neurotrophic factor (GDNF), a VA-invented biologic with demonstrated anti-obesity effects and metabolic regulation in preclinical models. The platform is protected under U.S. Patent No. 10,052,362 and targets multiple high-burden conditions, including non-alcoholic fatty liver disease (NAFLD), type 2 diabetes, and central obesity.

“With obesity at epidemic levels and no curative therapies available, we believe the VA’s biologic GDNF is potentially a game-changer,” said Eric Weisblum, CEO of Silo Pharma. “We believe that our potential JV collaboration with Hoth aligns with our mission to accelerate groundbreaking science into human trials.”

“This VA-originated obesity technology has the potential to disrupt a $16 billion market and deliver life-changing impact for millions, including veterans disproportionately affected by metabolic disorders,” added Robb Knie, CEO of Hoth Therapeutics. “We are proud to partner with Silo Pharma in an effort to bring this innovation to the public.”

Deal Highlights:

• Exclusive U.S. License from the U.S. Department of Veterans Affairs covering all fields of use
• 50/50 joint venture structure with equal equity and governance participation
• Lead indication: Obesity and NAFLD – conditions with prevalence among both civilian and veteran populations

Unmet Need:

Obesity affects over 40% of U.S. adults and is a leading risk factor for diabetes, cardiovascular disease, and liver failure. Veterans are especially impacted due to chronic inflammation, PTSD-linked metabolic disruption, and access challenges to effective care. There are no approved curative biologics targeting the neuroinflammatory root of obesity, a gap that this VA-originated technology is uniquely positioned to fill.

Strategic Alignment:

The partnership leverages:

• The clinical infrastructure and public mission of the VA
• Hoth’s regulatory and development expertise
• Silo’s translational capabilities and capital efficiency

About Silo Pharma

Silo Pharma Inc. (Nasdaq: SILO) is a developmental stage biopharmaceutical company focused on addressing underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system (CNS) diseases. The Company’s portfolio includes innovative programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer’s disease and multiple sclerosis. Silo’s research is conducted in collaboration with leading universities and laboratories. silopharma.com

Forward-Looking Statements
This news release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified using words “could”, “believe”, “anticipate”, “intend”, “estimate”, “expect”, “may”, “continue”, “predict”, “potential”, and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this press release, whether as a result of new information, future events, or otherwise, after the date of this press release or to reflect the occurrence of unanticipated events except as required by law.

Contact 800-705-0120
investors@silopharma.com

SOURCE: Silo Pharma, Inc.

The post Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market appeared first on CorporatePRwire.

After quietly working with LifeRx.md for nearly three years, Josephs recently went public about her experience with the company’s GLP‑1-based wellness program, revealing that she lost 23 pounds under medical supervision. But for Josephs, the benefits went well beyond weight.

In an exclusive Page Six Radio interview, she explained: “It wasn’t just about dropping pounds-it was about regaining my energy, confidence, and sense of control.”

Like many women navigating menopause, Josephs faced metabolic challenges that made traditional weight-loss methods-like dieting and exercising-less effective. Frustrated but determined, she turned to LifeRx.md, a telemedicine platform offering provider-supervised GLP‑1 treatments designed based on individual provider evaluation.

For Josephs, the convenience and flexibility of LifeRx.md’s model were game-changers. As a business owner, public figure, and frequent traveler, finding time for in-person doctor visits or rigid diet routines was unrealistic. LifeRx.md’s virtual consultations, personalized treatment plans, and home delivery service allowed her to stay consistent without sacrificing her demanding schedule.

“This plan was convenient and tailored to my needs,” Josephs said. “I had tried every method to lose weight, and nothing worked until this.”

The platform’s GLP‑1 program is designed for individuals experiencing changes in metabolism and hormone levels, including those brought on by menopause. By mimicking the body’s natural hunger-regulating hormones, GLP‑1 treatments may support appetite control, blood sugar balance, and weight management-all under ongoing clinical supervision.

“Margaret’s story reflects what so many people-especially women-are experiencing,” said Nic Sementas, spokesperson for LifeRx.md. “We’ve built our platform for busy, real-world patients who deserve solutions that are medically sound and sustainable.”

Starting at $250 for a five-week supply, LifeRx.md’s treatment plans don’t require insurance, contracts, or in-person appointments. Patients receive a full clinical evaluation, lab work, and continuous provider access-all designed to make wellness more accessible and less intimidating.

As someone who has spent years in the public eye, Josephs is no stranger to pressure around body image-but she’s been intentional about focusing her message on wellness, not vanity. “It was about feeling like myself again,” she shared, emphasizing how her energy levels and focus improved during treatment.

That clarity and vitality have made a difference not just in her health, but also in how she shows up professionally-from filming reality TV to running her business ventures. “It fit into my lifestyle without disrupting it, which is key when you have a million things going on,” she said.

Beyond the physical changes, Josephs has become an advocate for removing stigma around using medically-supervised support for weight and hormonal health. “Everybody needs a little help, and there’s no shame in it,” she said.

Her partnership with LifeRx.md aims to amplify that message-especially for midlife women often overlooked in the wellness space.

About Margaret Josephs
Margaret Josephs is a television personality, fashion entrepreneur, and public speaker. She’s widely recognized for her role on The Real Housewives of New Jersey and is known for her outspoken approach to entrepreneurship, lifestyle, and now, wellness.

About LifeRx.md
LifeRx.md is a national telehealth provider offering customized, GLP‑1-based health programs designed around individual metabolic and hormonal needs. With licensed clinicians, virtual consultations, and discreet delivery, the platform makes medically supervised wellness accessible, affordable, and personalized.

For media inquiries:
Email: press@liferxtelemd.com

The post Margaret Josephs Opens Up About Her Health Journey with LifeRx.md: “Power is a great look on me.” appeared first on CorporatePRwire.

INTRODUCTION

Access to quality healthcare and essential medications remains a critical challenge for millions, particularly in underserved communities. Against this backdrop, five pharmacists-Pharm. Emmanuel Segun Oluwagbade, Pharm. Oluwole Raphael Odumbo, Pharm. Chukwudi Anthony Okolue, Pharm. Oluchukwu Ogbuagu, and Pharm. Vincent Odunayo Alemede-have emerged as transformative leaders in the pharmaceutical sector. Each brings unique expertise and innovative solutions to address systemic challenges in medication access, supply chain management, and healthcare delivery.

This press release highlights their collective impact and individual contributions to revolutionizing pharmaceutical care, demonstrating how strategic innovation and compassionate leadership can overcome entrenched barriers to healthcare access.

PHARM. EMMANUEL SEGUN OLUWAGBADE: RE ENGINEERING MEDICINE SUPPLY CHAINS

Emmanuel Segun Oluwagbade has established himself as a pioneering pharmacist turned-supply-chain strategist whose innovations are transforming healthcare delivery from Lagos to the Mississippi Delta. With a business education from Vanderbilt University, he brings a unique perspective to the critical challenge of ensuring essential medicines reach those who need them most.

As a Medical Sales Consultant at Servier, the French multinational’s cardiovascular franchise in West Africa, Oluwagbade discovered that essential medicines like ACE inhibitors and anti-diabetics reached barely one-third of public pharmacies and primary healthcare institutions. In response, he launched targeted awareness campaigns and restructured distribution networks in Eastern Nigeria. His “Hear, Talk and See” and “Love Your Heart” initiatives reached over 1.5 million patients with new access to Gliclazide MR and Perindopril, contributing to reduced mortality rates in the region.

Oluwagbade’s redesign of the pharmaceutical supply chain used predictive analytics to forecast demand, slashing emergency stock-outs by 70% and reducing delivery lead

times from two weeks to just three days. These interventions dramatically cut medicine waste and reinforced his belief that supply-chain infrastructure is the hidden backbone of healthcare equity.

His vision extends beyond pharmaceutical logistics to AI-powered health innovations. He developed VaxMate, an AI-driven application that enhances vaccination workflows by providing community health workers with geofenced route plans and healthcare institutions with real-time dashboards to flag vaccine stock-outs. Early pilots in Southwest Nigeria increased on-time pentavalent vaccine coverage by 10%, with plans underway to integrate last-mile drone delivery.

Expanding this impact further, Oluwagbade co-founded Greeenin with public-health technologist Blessing Animasahun, securing seed funding and a partnership with the Ogun State government to combat food insecurity. The AI-powered platform connects families to food distribution centers, provides personalized nutrition guidance, and matches users with healthcare professionals.

Now preparing for seed rounds for both VaxMate and Greeenin, Oluwagbade is focused on scaling these solutions across global underserved regions. With government partnerships in place and early traction validated, he’s building data-driven infrastructure to accelerate access to essential vaccines and nutrition. “The vision is simple,” he says. “If we can build smarter systems, we can give millions a fairer shot at life.”

PHARM. OLUWOLE RAPHAEL ODUMBO: DIGITIZING HOSPITAL SUPPLY CHAINS

Pharmacist Oluwole Raphael Odumbo has successfully driven a groundbreaking achievement for the Nigerian healthcare system by implementing digital inventory tracking with RFID/barcode technology in major hospitals. With expertise in clinical pharmacy, supply chain management, operations, and project management gained from working with three multinational healthcare companies, Odumbo recognized the cost implications of inventory challenges on hospitals and healthcare delivery.

Over the past two years, Odumbo has championed this innovation to tackle long standing challenges including inventory inaccuracies, stockouts and overstocking, inefficiencies and wastage, medication errors, counterfeit medicines, and pilfering. His efforts were recognized during the 46th conference of the Association of Nigerian Private Medical Practitioners, where he received accolades in the presence of healthcare leaders and policymakers.

“Digitizing hospital inventory tracking with barcodes and RFID is a game-changer for Nigerian healthcare,” Odumbo states. “By reducing errors, enhancing efficiency, and ensuring essential supplies are always available, hospitals can save lives and reduce costs.” His collaborative approach extended to partnering with the Nigerian Medical

Association to raise awareness about the benefits of this technology.

The impact of Odumbo’s work is substantial and far-reaching. By simplifying complex issues in healthcare supply chain management, his solution eliminates manual counting errors, enables faster check-in and check-out of supplies, reduces time spent on inventory audits and replenishment, and helps combat fake drugs through verified supply chain tracking.

Odumbo’s collaborative leadership style prioritizes shared goals and measurable outcomes. Together with his team, they have fostered a movement demonstrating the value of solving complex supply chain issues in the Nigerian healthcare sector. His vision has set a benchmark for incorporating innovative solutions into the national healthcare system, driving sustainable improvements and delivering better health outcomes for generations to come.

PHARM. CHUKWUDI ANTHONY OKOLUE: FROM PERSONAL MISSION TO NATIONWIDE IMPACT

Chukwudi Anthony Okolue’s journey into pharmacy began with personal tragedy when he lost his mother due to limited access to healthcare in rural Nigeria. Originally set to study engineering, Okolue instead enrolled in pharmacy at the University of Nigeria, determined to ensure that no other family would suffer a preventable loss due to lack of access.

Okolue began his career at Nigeria’s National Agency for Food and Drug Administration and Control (NAFDAC), gaining firsthand insight into the country’s challenges with drug approval, counterfeit medications, and medical device regulation. Later, as Territory Sales Manager at Sanofi, he led the Southern Nigeria portfolio for thrombosis and diabetes care while initiating life-saving health campaigns.

His “Save the Feet” campaign tackled a widespread myth that diabetic foot ulcers were caused by curses or “juju”-a misconception that led many patients to seek traditional remedies or delay treatment, resulting in preventable amputations or deaths. With data showing amputation rates in Nigeria from diabetic foot ulcers as high as 52% and mortality near 18%, Okolue and his team launched regional health education efforts, reaching over 500 healthcare professionals. The result was better patient outcomes and

a 128% increase in access to appropriate therapies, earning him Sanofi’s prestigious Green Star Award in 2019.

Recognizing that over 90% of Nigerians lack health insurance and pay out-of-pocket for medications, Okolue co-founded BellsBag Pharmaceuticals in 2021 alongside Indian partners. The company focused on delivering affordable, high-quality essential medications to low-income Nigerians, building a supply chain that directly served over 140,000 Patent and Proprietary Medicine Vendors (PPMVs)-small, licensed drug sellers who provide frontline care to over 107 million Nigerians, especially in underserved areas.

Okolue’s entrepreneurial vision expanded with the launch of Paraclete Pharmacy, a retail health outlet in a densely populated, low-income area offering NAFDAC-approved medications, in-person consultations, and free screenings for chronic diseases. Most recently, in 2025, he co-founded Gentech Lifesciences, a telemedicine startup leveraging Nigeria’s growing mobile phone penetration to bring healthcare to rural and semi-urban populations.

“Health shouldn’t be a privilege,” Okolue says. “It should be a right-one that we build into every village, every street corner, every person’s life.” His work has touched virtually every layer of Nigeria’s healthcare ecosystem-from policy to public education, frontline distribution to digital innovation-impacting millions of lives through targeted innovation, local partnerships, and social entrepreneurship.

PHARM. OLUCHUKWU OGBUAGU: FROM CRISIS RESPONSE TO SYSTEM DESIGN

Before global supply chains began to unravel in the wake of COVID-19, Oluchukwu Ogbuagu, then leading the cardiovascular business unit at a top multinational pharmaceutical company in Nigeria, was already thinking ahead. He recognized the structural risks in Nigeria’s overreliance on imported medications and had begun advocating internally for supply diversification, local manufacturing partnerships, and predictive inventory modeling to strengthen system resilience. When the pandemic struck, these ideas shifted from foresight to frontline necessity.

Anticipating prolonged stockouts, Ogbuagu initiated a pilot project using digital simulation tools to model drug availability under crisis scenarios. The insights allowed him to restructure distribution strategies in real-time, prioritizing continuity of care despite systemic disruptions. He also worked directly with prescribers to deploy dual monotherapy regimens in place of unavailable fixed-dose combinations, ensuring patients remained on treatment without compromising efficacy.

Beyond tactical adaptation, he led the development of a machine learning-enabled SKU optimization tool that analyzed regional prescribing patterns and disease prevalence data. This allowed his team to align previously underutilized cardiovascular medicines with high-need geographies and providers. The result: a 75%, 60%, and 50% increase in uptake for three low-demand SKUs in a single quarter, despite widespread product shortages.

After his tenure at the pharmaceutical company, Ogbuagu turned his focus to access driven innovation. He channeled his insights into expanding Aguata Pharmacy, his family’s healthcare business, which had long served as a trusted pharmaceutical retail and distribution network. He leveraged Aguata’s existing infrastructure to register and launch low-cost essential medicines, aiming to increase access in underserved communities where affordability remains a primary barrier.

But distribution wasn’t enough. Ogbuagu paired the rollout with a tele-pharmacy consultation service, allowing patients in remote areas to receive virtual guidance on safe and effective usage. To safeguard product integrity, he implemented a blockchain based traceability system, enabling authentication of each unit of product from manufacturer to dispenser, enhancing safety and trust.

Further scaling impact, he piloted mobile health pop-up units in Enugu State, combining drug access with community health screenings, digital referrals, and patient education, bringing healthcare directly to the last mile.

Recognizing the systemic lessons from his experience, Ogbuagu co-authored a crisis response playbook for medication continuity during health emergencies. This model has since been adopted by public health stakeholders and shared with state health authorities as a replicable framework for future disruptions.

He continues to advocate for policy reform that supports local pharmaceutical manufacturing, transparent supply chains, and agile emergency preparedness in Nigeria’s health system.

“Resilience isn’t built in the chaos,” Ogbuagu reflects. “It’s built in the quiet, when we’re designing systems to withstand what hasn’t happened yet.”

PHARM. VINCENT ODUNAYO ALEMEDE: OPTIMIZING GLOBAL PHARMACEUTICAL SUPPLY CHAINS

Vincent Odunayo Alemede has established himself as a pioneer in pharmaceutical supply chain management across three continents. With an educational foundation that includes a Bachelor of Pharmacy from the University of Jos, a master’s degree in

Biotechnology from the University of Chester, and an MBA from Vanderbilt University’s Owen Graduate School of Management, Alemede brings a powerful combination of clinical knowledge, regulatory insight, and global logistics strategy to healthcare systems.

Beginning his career as a retail pharmacist in Nigeria, Alemede identified critical inefficiencies in the fragmented community pharmacy system. As superintendent pharmacist, he spearheaded two pharmacy acquisitions and developed operational integration models that significantly enhanced medication access for rural and peri urban communities. His empathy-driven innovations improved patient outcomes and boosted local engagement by over 60%, while his negotiated bulk procurement deals increased medication availability through economies of scale.

Alemede’s commitment to pharmaceutical integrity was evident early in his career when, as an intern with the Pharmacy Council of Nigeria, he contributed to shutting down counterfeit drug operations valued at over $35 million. “Protecting the drug supply is not just about regulation, it’s about trust,” Alemede explains. “Patients need to believe their medicines will heal, not harm.”

His impact extended internationally at an NHS hospital in the UK, where he implemented data-driven strategies including a point-of-sale inventory management system that reduced medication expiries and out-of-stock situations by 35%. Alemede’s cross-continental perspective informs his vision for pharmaceutical ecosystems that are both profitable and equitable. “Working across Nigeria, the UK, and the U.S. has shown me that medicine supply issues aren’t always about scarcity, they’re about structure,” he notes. “When we fix the system, we save lives.”

CONCLUSION

These five pharmacists-Pharm. Emmanuel Segun Oluwagbade, Pharm. Oluwole Raphael Odumbo, Pharm. Chukwudi Anthony Okolue, Pharm. Oluchukwu Ogbuagu, and Pharm. Vincent Odunayo Alemede-exemplify how pharmaceutical professionals can drive transformative change in healthcare systems. Through their diverse approaches to addressing medication access, supply chain optimization, digital innovation, and community engagement, they are collectively reshaping the landscape of pharmaceutical care.

Their work demonstrates that sustainable improvements in healthcare delivery require not only technical expertise but also compassionate leadership, innovative thinking, and a deep commitment to serving underserved communities. As healthcare systems worldwide continue to face unprecedented challenges, the contributions of these

visionary pharmacists offer valuable models for building more resilient, equitable, and effective pharmaceutical care.

Company name: Ignite Solutions

Website: ignitecds.com

Contact Number: +12029329427

The post TRANSFORMING HEALTHCARE ACCESS: FIVE PHARMACISTS REVOLUTIONIZING PHARMACEUTICAL CARE IN AFRICA AND BEYOND appeared first on CorporatePRwire.

CHARLESTON, SC / CorporatePRwire / March 28, 2025 / Manzo Eye Care is a leading provider of affordable and high-quality eye testing equipment. They are excited to announce new partnerships. They are teaming up with well-known industry leaders Haag Streit, iCare, and Nidek.

Manzo Eye Care dedicates itself to providing advanced and reliable eye testing solutions. We are partnering with optometrists and eye care professionals across the country.

“At Manzo Eye Care, we support optometrists and eye care professionals. We partner with industry leaders like Haag Streit, iCare, and Nidek,” said the CEO of Manzo Eye Care, Seanna Mattison.

“These collaborations enable us to deliver exceptional quality and unparalleled support to our clients consistently. Our main goal is to ensure that every practice can use the best research and diagnostic tools. This keeps them leading in eye care technology and patient care.

Manzo Eye Care focuses on improving eye care. We provide equipment that makes eye testing accurate, reliable, and efficient. Through these partnerships, the company builds its role as a trusted partner. It helps eye care providers with new technologies that improve patient outcomes.

About Manzo Eye Care

Manzo Eye Care is committed to providing eye care professionals with affordable and high-quality eye test equipment. The company focuses on accurate and reliable eye testing solutions. It provides professionals with the latest tools for better patient care. With a reputation built on excellence, Manzo Eye Care continues to support optometrists and eye care professionals nationwide.

For more information, visit https://manzoeyecare.com/about/.

Media Contact

Seanna Sonya, Public Relations Manager

Manzo Eye Care

+1 843-410-4911

sales@manzoeyecare.com

https://manzoeyecare.com/

The post Manzo Eye Care Announces Strategic Partnerships to Deliver Eye Test Equipment to Eye Care Professionals appeared first on CorporatePRwire.

Led by Pharm. Otuto Amarauche Chukwu, Precious Azino Usuemerai, Dr. Cordia Peter Ogbeta, and Pharm. Olumide Ibikunle, this strategic initiative should address supply chain vulnerabilities, regulatory inefficiencies, and infrastructural limitations while positioning Nigeria as a leading manufacturer and exporter of Active Pharmaceutical Ingredients (APIs) and essential medicines.

With over 70% of Nigeria’s medicines currently imported, the country remains exposed to global disruptions, currency fluctuations, and quality control issues. This initiative seeks to catalyze investments, drive policy reform, and enhance industrial capacity to create a resilient, locally driven pharmaceutical ecosystem that benefits Nigeria and Africa at large.

Nigeria’s Untapped Potential

“Crude oil isn’t just energy; it’s the backbone for petrochemicals essential in producing Active Pharmaceutical Ingredients (APIs),” asserts Precious Azino Usuemerai. “With the right infrastructure, we can foster job creation, boost economic growth, and ensure medicines security for millions,” Mr Usuemerai adds.

Building on this foundation, Pharm. Olumide Ibikunle, a Clinical Pharmacist and an MBA graduate from Vanderbilt University highlights another resource Nigeria is poised to leverage: its rich biodiversity. “Medicinal plants offer unique APIs that could revolutionize therapeutic approaches globally,” he notes. Dr. Ibikunle’s research on digital health marketing and predictive analytics demonstrates how data-driven strategies can optimize supply chains, improve patient engagement, and position Nigeria as a leader in pharmaceutical innovation. By patenting discoveries and standardizing therapies, Nigeria could emulate the global success of China’s Traditional Chinese Medicine industry, driving innovation while preserving biodiversity.

“Energy inefficiency is crippling the sector,” observes Dr. Cordia Peter Ogbeta, the Pharmacist Director of Showcare Pharmacy Ltd, Nigeria and a seasoned formulation scientist whose innovations have redefined operational sustainability in pharmaceutical production in Nigeria. Ogbeta’s efforts in implementing antimicrobial stewardship programs have improved medication compliance and reduced waste, directly benefiting thousands of underserved individuals. He emphasizes how rising petrol costs and unreliable power supply force manufacturers to rely on expensive generators. “Targeted subsidies and renewable energy adoption are critical for reducing operational costs and ensuring sustainability,” the Hult MBA graduate explains.

The Challenges and Solutions

For Mr Otuto Chukwu, addressing regulatory inefficiencies is paramount. “The influx of counterfeit medicines is a symptom of inadequate regulatory oversight,” he says. “Strengthening agencies like NAFDAC and providing them with adequate funding can safeguard quality control and restore trust in locally manufactured medicines.”

Building on this, Mr Usuemerai stresses the importance of aligning policy with local manufacturing needs. “Removing tariffs on imported medicines may seem consumer-friendly, but it undermines local manufacturers. Incentivizing API imports and prioritizing domestic production is the way forward. It’s about long-term growth over short-term convenience,” they argue.

Pharm Ibikunle highlights how frameworks like the African Continental Free Trade Area (AfCFTA) can be leveraged for regional collaboration. “Harmonizing regulatory standards and leveraging regional markets can create economies of scale that benefit all players,” he explains.

Dr Ogbeta, meanwhile, underscores the importance of sustainability. “Eco-friendly practices in petrochemical and pharmaceutical industries reduce waste and attract green investments,” he says. His leadership in antimicrobial stewardship and waste reduction illustrates how operational excellence can align with environmental goals.

Vision for the Future

By 2030, Nigeria could become a leading exporter of APIs, driving economic prosperity not only within its borders but across Africa. This growth would not only reduce dependency on imports but also establish the continent as a critical supplier in the global pharmaceutical value chain. Such progress would create a ripple effect, strengthening public health systems and fostering economic resilience throughout Africa. This vision depends on bold reforms and strategic collaboration among policymakers, industry leaders, and academic institutions.

Mr Usuemerai frames this vision through a human lens. “Ultimately, this isn’t just about economics or industrialization. It’s about ensuring that every Nigerian has access to safe, affordable medicines. By de-risking the pharmaceutical sector, we’re investing in lives, livelihoods, and the future of Africa.”

Call to Action: Be Part of the Transformation

This strategy is not just about industrial growth, it is about saving lives, strengthening Nigeria’s economy, and securing Africa’s future.

The coalition invites policymakers, pharmaceutical companies, investors, and global health organizations to collaborate on this transformative journey.

About this Strategy

This strategy is led by Dr. Cordia Peter Ogbeta, Otuto Amarauche Chukwu, Pharm. Olumide Ibikunle, and Precious Azino Usuemerai, and, a coalition of leading experts in pharmaceutical innovation, health policy, and sustainability, committed to transforming Nigeria’s pharmaceutical sector and making Africa self-sufficient in medicine production.

Media Contact: 

Cordia Peter Ogbeta

Phone: +2349136400664 

The post Official Announcement: Strategic Initiative Launched to Revolutionize Pharmaceutical Manufacturing and Strengthen Africa’s Medicine Security appeared first on CorporatePRwire.